<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25006583</PMID><DateCompleted><Year>2015</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2314-6141</ISSN><JournalIssue CitedMedium="Internet"><Volume>2014</Volume><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>BioMed research international</Title><ISOAbbreviation>Biomed Res Int</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.</ArticleTitle><Pagination><StartPage>670506</StartPage><MedlinePgn>670506</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">670506</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2014/670506</ELocationID><Abstract><AbstractText>We assessed two strategies for preparing candidate vaccines against hand, foot, and mouth disease (HFMD) caused mainly by infections of enterovirus (EV) 71 and coxsackievirus (CV) A16. We firstly design and optimize the potency of adjuvant combinations of emulsion-based delivery systems, using EV71 candidate vaccine as a model. We then perform immunogenicity studies in mice of EV71/CVA16 antigen combinations formulated with PELC/CpG. A single dose of inactivated EV71 virion (0.2 &#x3bc;g) emulsified in submicron particles was found (i) to induce potent antigen-specific neutralizing antibody responses and (ii) consistently to elicit broad antibody responses against EV71 neutralization epitopes. A single dose immunogenicity study of bivalent activated EV71/CVA16 virion formulated with either Alum or PELC/CpG adjuvant showed that CVA16 antigen failed to elicit CVA16 neutralizing antibody responses and did not affect EV71-specific neutralizing antibody responses. A boosting dose of emulsified EV71/CVA16 bivalent vaccine candidate was found to be necessary to achieve high seroconversion of CVA16-specific neutralizing antibody responses. The current results are important for the design and development of prophylactic vaccines against HFMD and other emerging infectious diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Chia-Chyi</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-6257-0389</Identifier><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Tsung-Chun</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shih-Jen</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">0000-0002-8736-1452</Identifier><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan ; Graduate Institute of Immunology, China Medical University, Taichung 40402, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Yen-Hung</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Pele</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4197-7160</Identifier><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan ; Graduate Institute of Immunology, China Medical University, Taichung 40402, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming-Hsi</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Town, Miaoli County 35053, Taiwan ; Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biomed Res Int</MedlineTA><NlmUniqueID>101600173</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C408982">CPG-oligonucleotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004655">Emulsions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009838">Oligodeoxyribonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004655" MajorTopicYN="N">Emulsions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009838" MajorTopicYN="N">Oligodeoxyribonucleotides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="Y">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>6</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25006583</ArticleId><ArticleId IdType="pmc">PMC4071850</ArticleId><ArticleId IdType="doi">10.1155/2014/670506</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD) 2011.</Citation></Reference><Reference><Citation>Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. Clinical features, diagnosis, and management of enterovirus 71. The Lancet Neurology. 2010;9(11):1097&#x2013;1105.</Citation><ArticleIdList><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. The Lancet Infectious Diseases. 2010;10(11):778&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Hsieh S-Y, Liu C-C, et al. Production of EV71 vaccine candidates. Human Vaccines and Immunotherapeutics. 2012;8(12):1775&#x2013;1783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung C-P, Liu C-C, et al. A phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine. 2013;31(20):2471&#x2013;2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F-C, Meng F-Y, Li J-X, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2013;381(9882):2024&#x2013;2032.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. The New England Journal of Medicine. 2014;370(9):818&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children. The New England Journal of Medicine. 2014;370(9):829&#x2013;837.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P, Guo M-S, Lin FH-Y, et al. Immunological and biochemical characterization of coxsackie virus A16 viral particles. PLoS ONE. 2012;7(11)e49973</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511423</ArticleId><ArticleId IdType="pubmed">23226233</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Y, Liu Q, Huang X, et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine. 2013;31(18):2215&#x2013;2221.</Citation><ArticleIdList><ArticleId IdType="pubmed">23499596</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel FR, Caillet C, Kusters IC, Haensler J. Emulsion-based adjuvants for influenza vaccines. Expert Review of Vaccines. 2009;8(4):483&#x2013;492.</Citation><ArticleIdList><ArticleId IdType="pubmed">19348563</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(30):10501&#x2013;10506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2483233</ArticleId><ArticleId IdType="pubmed">18650390</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M-H, Huang C-Y, Lin S-C, et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes and Infection. 2009;11(6-7):654&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pubmed">19344782</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang M-H, Lin S-C, Hsiao C-H, et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS ONE. 2010;5(8)e12279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924384</ArticleId><ArticleId IdType="pubmed">20808862</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S-C, Huang M-H, Tsou P-C, Huang L-M, Chong P, Wu S-C. Recombinant trimeric HA protein immunogenicity of H5N1 avian influenza viruses and their combined use with inactivated or adenovirus vaccines. PLoS ONE. 2011;6(5)e20052</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3104987</ArticleId><ArticleId IdType="pubmed">21655326</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S-C, Jan J-T, Dionne B, et al. Different immunity elicited by recombinant H5N1 hemagglutinin proteins containing pauci-mannose, high-mannose, or complex type N-glycans. PLoS ONE. 2013;8(6)e66719</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682957</ArticleId><ArticleId IdType="pubmed">23799128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CW, Chang CY, Chen WL, et al. Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Human Vaccine &amp; Immunotherapeutics. 2013;9(11):2378&#x2013;2385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3981847</ArticleId><ArticleId IdType="pubmed">23838466</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Guo M-S, Lin FH-Y, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS ONE. 2011;6(5)e20005</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3094384</ArticleId><ArticleId IdType="pubmed">21603631</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C-C, Chou A-H, Lien S-P, et al. Identification and characterization of a cross-neutralization epitope of enterovirus 71. Vaccine. 2011;29(26):4362&#x2013;4372.</Citation><ArticleIdList><ArticleId IdType="pubmed">21501643</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger R, Just M, Gluck R. Interference between strains in live virus vaccines I: combined vaccination with measles, mumps and rubella vaccine. Journal of Biological Standardization. 1988;16(4):269&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pubmed">3198657</ArticleId></ArticleIdList></Reference><Reference><Citation>Guy B, Barban V, Mantel N, et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. The American Journal of Tropical Medicine and Hygiene. 2009;80(2):302&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">19190230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Edelman R, Kanesa-Thasan N, et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. The American Journal of Tropical Medicine and Hygiene. 2003;69(6):24&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">14740952</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Singh M. Selection of adjuvants for enhanced vaccine potency. World Journal of Vaccine. 2011;1(2):33&#x2013;78.</Citation></Reference><Reference><Citation>Vesikari T, Pellegrini M, Karvonen A, et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. The Pediatric Infectious Disease Journal. 2009;28(7):563&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pubmed">19561422</ArticleId></ArticleIdList></Reference><Reference><Citation>Song YC, Cheng HY, Leng CH, et al. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. Journal of Control Release. 2014;173:158&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">24177312</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler CM, Castellsagu&#xe9; X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology. 2012;13(1):100&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">22075170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L-Y, Hsiung CA, Lu C-Y, et al. Status of cellular rather than humoral immunity is correlated with clinical outcome of enterovirus 71. Pediatric Research. 2006;60(4):466&#x2013;471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7086547</ArticleId><ArticleId IdType="pubmed">16940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y-W, Yu S-L, Shao H-Y, et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS ONE. 2013;8(2)e57591</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581494</ArticleId><ArticleId IdType="pubmed">23451246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang H-W, Lin Y-W, Ho H-M, et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS ONE. 2013;8(7)e69858</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3728341</ArticleId><ArticleId IdType="pubmed">23936115</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>